TECENTRIQ + Nab Paclitaxel

Keeping patients with TNBC connected to life

IMpassion 130 is the first positive Phase 3 trial for a cancer immunotherapy combination in first-line metastatic TNBC.1

Advanced TNBC is an aggressive breast cancer with poor prognosis

Unresectable locally advanced or metastatic triple-negative (hormone-receptor–negative and human epidermal growth factor receptor 2 [HER2]–negative) breast cancer (TNBC) is an aggressive disease, which has been associated with poor outcomes.1




A woman having a breast scan.


A paradigm shift in first-line advanced TNBC. The first cancer immunotherapy combination to extend survival in PD-L1+ advanced TNBC.

TECENTRIQ indications 


TECENTRIQ in combination with nab-paclitaxel (nab-pac) is indicated for the treatment of adult patients with unresectable locally advanced or metastatic TNBC whose tumours have PD-L1 expression ≥1% and who have not received prior chemotherapy for metastatic disease.2

IMpassion130: A robust Phase 3 efficacy trial evaluating TECENTRIQ + nab-pac in advanced TNBC3


A Phase 3 trial of 902 patients with metastatic triple-negative breast cancer receiving atezolizumab plus nab-pac or placebo nab-pac.3 Primary end points progression-free survival (in the intention-to-treat population and PD-L1+subgroup) and OS. Treatment continued until disease progression or an unacceptable level of toxic effects occurred. Patients were stratified by prior neoadjuvant or adjuvant taxane therapy, liver metastases at baseline, and PD-L1 expression.


41% of patients in IMpassion130 had PD-L1+ disease, defined as ≥1% expression on IC using the Ventana SP142 assay.3

  • dddd

    Median OS was 25 months with TECENTRIQ + nab-pac in the PD-L1+ population3

    Clinically meaningful OS improvement of 7 months with TECENTRIQ + nab-pac3

    Nab-pac, nab-paclitaxel; OS, overall survival.
    *As per the prespecified analysis hierarchy, OS comparisons between treatment arms in the PD-L1+ population were not formally tested in this interim analysis, and the result is provided for descriptive purposes only.

  • dddd

    Improved median PFS of 7.5 months vs 5 months with nab-pac alone in the PD-L1+ population1

    Significantly prolonged median PFS with TECENTRIQ in combination with nab-pac versus nab-pac alone (7.5 months vs 5.0 months; HR=0.62; 95% CI: 0.49, 0.78; p<0.0001)​.

    Nab-pac, nab-paclitaxel; PD-L1, programmed death-ligand 1; PFS, progression-free survival.

A new standard of extended survival in patients with PD-L1+ advanced TNBC1

  • dddd

    Expression of PD-L1 ≥1% in tumour infiltrating IC was predictive of benefit in patients undergoing treatment with TECENTRIQ in combination with nab-pac3*

    Median OS in patients with PD-L1+ TNBC was 25.0 months (95% CI: 19.6, 30.7) with TECENTRIQ plus nab-pac vs 18.0 months (95% CI: 13.6, 20.1) with placebo plus nab-pac (stratified HR=0.71; 95% CI: 0.54, 0.94).

    IC, immune cells; nab-pac, nab-paclitaxel; PD-L1, programmed death-ligand 1.
    *As per the prespecified analysis hierarchy, OS comparisons between treatment arms in the PD-L1+ population were not formally tested in this interim analysis, and the result is provided for descriptive purposes only.

What this means for patients with TNBC


Testing TNBC patients for PD-L1 status with the SP142 assay (IC≥1%) at metastatic diagnosis will help you select patients for TECENTRIQ in combination with nab-paclitaxel and improve first-line outcomes.


Curious to see more resources and download material?



At Roche, we believe in a shared purpose in improving the care and treatment of patients living with difficult to treat cancers. We understand and empathise with the demands you face managing the needs of these patients.

Roche is committed to exploring new treatment options to individualise treatment and meet patients’ needs. TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to exploring new combinations to improve patient outcomes (ref. SmPC). 

TECENTRIQ is an anti PD-L1 cancer immunotherapy that specifically targets PD-L1 on tumour and tumour-infiltrating immune cells across a broad range of solid tumours. TECENTRIQ offers a pioneering, targeted treatment with proven efficacy and an acceptable tolerability profile (ref. SmPC). Please see the specific indications for more information.

A female research scientist wearing glasses.


TECENTRIQ has proven efficacy as monotherapy as well as in combination with other medicines and we are committed to explore new combinations for better patient outcomes (ref. SmPC).

In many difficult-to-treat tumour types with a high unmet need, including metastatic urothelial carcinoma, triple negative breast cancer and lung cancer (non-small cell lung cancer and small cell lung cancer), TECENTRIQ has shown significant improvements in progression-free and/or overall survival (ref. SmPC). Importantly, treatment can be tailored (i.e., in combination with the standard of care, or different dosing schedules) according to the type of cancer and the patient’s individual needs (ref. SmPC).
Read SmPC for more details

The multiple indications of TECENTRIQ (ref. SmPC)
provide a wealth of data to inform treatment decision-making and deliver valuable reassurance when considering the needs of your patients with cancer. Please see the specific indications for more information.



TECENTRIQ treatment offers the potential to improve treatment outcomes and maintain patient quality of life in your difficult to treat cancer patients, so they can hopefully spend more time with their loved ones.

TECENTRIQ is approved in metastatic urothelial carcinoma, non-small cell lung cancer, extensive-stage small cell lung cancer and triple negative breast cancer (ref. SmPC).

  • References & Notes


    ES-SCLC, extensive-stage small-cell lung cancer; HCC, hepatocellular carcinoma; metastatic TNBC, triple-negative breast cancer.

  • References & Notes

    References & Notes

    1. Schmid P, et al; IMpassion130 Trial Investigators. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med. 2018;379:2108–21.


    2. TECENTRIQ (atezolizumab), Summary of Product Characteristics. Roche.


    3. Schmid P, et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2020;21:44–59.


    4. Sabari JK, et al. Unravelling the biology of SCLC: implications for therapy. Nat Rev Clin Oncol. 2017;14:549–61.


    5. Horn L, et al. IMpower133 Study Group. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220–9.


    6. Rosenberg JE, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.


    7. Powles T, et l. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2018;391(10122):748–57.